Description |
InvivoChem Cat #:V5027CAS #:2172651-73-7Purity >=98%Description: RMC-4550 is a novel, potent, selective and allosteric inhibitor of SHP2 phosphatase with an IC50 of 0.583 nM. RMC-4550 is a potent and selective SHP2 inhibitor. RMC-4550 identified as a high quality tool compound to study the role of SHP2 in tumor biology, both in vitro and in vivo in rodents. SHP2 is a convergent signalling node and inhibition of SHP2 is effective in targeting both upstream (RTK-driven) and downstream (RAS-GTP dependent) mutations in the RAS-MAPK pathway. Oncogenic alterations in the RAS/RAF/MEK/ERK pathway drive the growth of a wide spectrum of cancers. While BRAF and MEK inhibitors are efficacious against BRAFV600E-driven cancers, effective targeted therapies are lacking for most cancers driven by other pathway alterations, including non-V600E oncogenic BRAF, RAS GTPase-activating protein (GAP) NF1 (neurofibromin 1) loss and oncogenic KRAS.
References: Nat Cell Biol. 2018 Sep; 20(9):1064-1073. |
![RMC-4550]()
|
Name: RMC-4550 CAS#: 2172651-73-7 Chemical Formula: C21H26Cl2N4O2 Exact Mass: 436.1433 Molecular Weight: 437.365 Elemental Analysis: C, 57.67; H, 5.99; Cl, 16.21; N, 12.81; O, 7.32 |
Technical Information |
Synonym: RMC4550; RMC 4550; RMC-4550. Chemical Name: (3-((3S, 4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(2, 3-dichlorophenyl)-5-methylpyrazin-2-yl)methanol InChi Key: IKUYEYLZXGGCRD-ORAYPTAESA-N InChi Code: InChI=1S/C21H26Cl2N4O2/c1-12-18(14-4-3-5-15(22)17(14)23)26-16(10-28)20(25-12)27-8-6-21(7-9-27)11-29-13(2)19(21)24/h3-5, 13, 19, 28H, 6-11, 24H2, 1-2H3/t13-, 19+/m0/s1 SMILES Code: ClC1=C(Cl)C(C2=NC(CO)=C(N3CCC4(CO[CH](C)[CH]4N)CC3)N=C2C)=CC=C1 |